The invention relates to a family of differently substituted benzothiazoles having inhibitory activity against casein kinase 1 (CK-1) enzyme, as a result of which they are suitable for use in the treatment or prevention of diseases caused by this enzyme, particularly diseases associated with circadian rhythm and inflammatory, autoimmune, psychiatric, neurodegenerative, neurological or ophthalmic diseases, as well as for inducing cell regeneration